Hubbry Logo
CodrugCodrugMain
Open search
Codrug
Community hub
Codrug
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Contribute something
Codrug
Codrug
Codrug
View on Wikipedia
from Wikipedia

A codrug consists of two drug moieties, generally "active against the same disease", that are joined through one or more covalent chemical bonds to create a single new chemical entity;[1] they can also be described as a mutual prodrug, recognising that a catabolic biosynthetic step is most often required to liberate the two drugs.[2] While acting against the same disease, the two moities may operate via different mechanisms of action, and so display differing specific therapeutic effects.[citation needed] The recognised advantages of a codrug approach to small molecule drug design include the possibilities of (i) combined efficacies of the two drugs that are therapeutically synergistic, (ii) altered properties that improve the pharmacokinetics (e.g., halflife) of the codrug over its individually administered components (iii) improved modes of drug delivery, and (iv) masking of reactive functional groups of each component drug, possibly improving shelf life (as well as pharmacokinetics).[1][2]

Elements of codrug design

[edit]

An effective codrug should be pharmacologically inactive in its own right but should release the constituent drugs upon biochemical breakage of the chemical linkage at the target tissue where their therapeutic effects are needed. As such, the chemical linkage (usually a covalent bond) should be subjectable to biodegradation, such as hydrolysis, by an enzymatic or non-enzymatic mechanism. The differential distribution of enzymes capable of catalyzing the breakage of the chemical linkage in different tissues may be exploited to achieve tissue-specific metabolism of the codrug to release the constituent drugs.

Common codrugs

[edit]

References

[edit]

See also

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Codrug

View on Grokipedia
from Grokipedia
A codrug, also known as a mutual , is a pharmacological entity formed by covalently linking two or more active molecules, which are designed to undergo cleavage in the body to release the individual parent compounds, thereby optimizing their therapeutic profile. This approach differs from traditional prodrugs by directly coupling the active moieties or using a cleavable spacer, enabling synergistic effects or targeted delivery without fundamentally altering the drugs' inherent . The concept of codrugs emerged in the mid-20th century, with the first clinically utilized example being , introduced in 1942 as a treatment for by combining (an antibacterial) and 5-aminosalicylic acid (an ). Initially developed to mitigate the toxicity of , later found primary application in treating due to its targeted release in the colon. A subsequent early codrug, benorylate (an ester linkage of and acetylsalicylic acid), was developed for managing and musculoskeletal disorders, offering combined and benefits with potentially reduced gastric irritation. Codrugs provide several key advantages over conventional drug combinations, including enhanced , improved across biological membranes (such as or the blood-brain barrier), prolonged , and decreased adverse effects through site-specific . These properties make them particularly valuable for addressing challenges in treating conditions like neurodegenerative diseases, cardiovascular disorders, cancer, infections, and , where simultaneous delivery of synergistic agents can amplify efficacy. While many codrugs remain in preclinical or early clinical stages, their design facilitates better outcomes, such as increased for oral or administration, though further clinical trials are essential to expand their therapeutic applications.

Definition and Background

Definition

A codrug, also known as a mutual , is a single chemical entity composed of two or more pharmacologically active moieties covalently linked together, rendering the conjugate inactive until cleavage releases the individual active components. In this design, each serves as a promoiety for the other, enabling mutual bioactivation through metabolic processes. This approach addresses limitations of the parent drugs, such as poor or rapid , by leveraging the linked for improved delivery. Unlike traditional prodrugs, which consist of an inactive precursor linked to a single active via an inert carrier group that is cleaved to release only the active moiety, codrugs involve two or more active agents where the linkage mutually enhances the pharmacokinetic or pharmacodynamic properties of both. Codrugs thus provide reciprocal benefits, as the promoiety derived from one can improve the absorption, distribution, or targeting of the other, distinguishing them from unidirectional prodrug activation. In contrast to combination drugs, which are physical mixtures or co-formulations of separate administered together without chemical bonding, codrugs form a unified via covalent bonds, ensuring synchronized release and potentially better compliance and efficacy. The basic mechanism of codrug relies on bioreversible cleavage at the target site, typically through enzymatic , non-enzymatic , or reduction of the labile linker (such as , , or bonds), exploiting specific physiological conditions like , enzymes, or environments to liberate the active drugs. This site-specific release minimizes systemic exposure and enhances therapeutic precision, as the intact codrug remains pharmacologically inert until reaching the intended location.

Historical Development

The concept of codrugs originated in the 1930s and 1940s through empirical discoveries aimed at improving , with serving as an early example. Synthesized in 1942 by Swedish physician Nanna Svartz, was initially developed as an antibacterial agent for treating , based on the prevailing theory of bacterial etiology for the disease. By the 1970s, its therapeutic efficacy in led to recognition as a codrug, as colonic cleave the azo linkage to release the active components 5-aminosalicylic acid () and (antibacterial). The formalization of the mutual prodrug—or codrug—concept occurred in the 1970s, building on earlier strategies to link two pharmacologically active agents for synergistic delivery and reduced toxicity. Researchers, including Huttunen et al., highlighted this approach in seminal reviews, emphasizing bioreversible linkages that release both components . A key early milestone was the approval of benorylate in 1971, an ester-linked codrug of aspirin and designed to provide sustained analgesia while minimizing gastrointestinal irritation from aspirin alone. During the and , codrug development expanded significantly in applications, driven by the need to mitigate side effects of non-steroidal drugs (NSAIDs) like and through targeted linkages. The 2000s marked a surge in codrugs for anticancer and targeted delivery, with optimization strategies focusing on improving and site-specific release, as exemplified by reviews on mutual prodrugs for . Regulatory milestones included early FDA approvals in the mid-20th century for gastrointestinal codrugs like (1950 for ). Post-2000, codrug evolution shifted from empirical synthesis to rational , incorporating computational modeling to predict linker stability, cleavage kinetics, and pharmacokinetic profiles for enhanced precision. This transition has facilitated broader applications in and combination therapies.

Design and Synthesis

Principles of Codrug

Codrugs, also known as mutual prodrugs, are designed by covalently linking two pharmacologically active agents, each serving as a promoiety for the other, to create an inactive conjugate that enhances therapeutic while addressing limitations such as poor or . The core principle involves selecting synergistic drug pairs that target the same disease pathway, such as two analgesics for or dual anticancer agents, to amplify combined effects while masking reactive functional groups that could cause adverse reactions during systemic circulation. A fundamental is the biodegradability of the codrug, ensuring it remains pharmacologically inert until cleaved by target-specific enzymes, such as esterases in inflamed tissues or pH-dependent in acidic environments, to release the unaltered active drugs without generating toxic byproducts. This site-selective exploits endogenous biological processes to control drug release, minimizing off-target exposure. Design principles emphasize maintaining the individual potencies of the released drugs, avoiding any chemical modifications that could impair their activity post-cleavage. Synergy is exploited through strategic pairing to achieve improved , such as enhanced absorption via increased or altered metabolic pathways that prolong duration of action, while ensuring the conjugate's overall stability during transit. Factors guiding pair selection include physicochemical compatibility, where drugs with balanced are preferred to optimize without compromising , and minimal steric interference at linkage sites to facilitate efficient cleavage. Tissue-specific targeting is achieved by leveraging differential distributions, for instance, utilizing bacterial azoreductases in the gut for gastrointestinal codrugs to localize release in the colon. An early example illustrating these principles is benorylate, a codrug of aspirin and , which reduces gastrointestinal irritation through targeted activation. Recent research has applied these principles to develop codrugs like the and heme oxygenase-1 inhibitor conjugate for treatment, demonstrating potential in .

Linker Strategies and Chemistry

Linker strategies in codrug design primarily involve the covalent attachment of two drug moieties through metabolically labile bonds that enable site-specific cleavage and of active components. The choice of linker balances chemical stability during synthesis and storage with controlled lability in physiological environments, ensuring efficient decoupling without generating toxic byproducts. Common linker types include esters, amides, and azo bonds, each tailored to specific cleavage triggers and therapeutic targets. Ester linkers, represented generally as R1−\ceCOO−R2R_1 - \ce{COO} - R_2, are the most prevalent due to their susceptibility to hydrolytic cleavage. These bonds form between a group of one drug and a hydroxyl group of another, providing a labile connection that mimics natural substrates. linkers, denoted as R1−\ceCONH−R2R_1 - \ce{CONH} - R_2, offer greater stability against spontaneous compared to esters, relying on enzymatic amidases for cleavage and thus suitable for applications requiring prolonged circulation. Azo linkers (R1−\ceN=N−R2R_1 - \ce{N=N} - R_2) are bioreductive, designed for gut-specific through bacterial azoreductases, enabling targeted delivery in the colon while remaining intact in upper conditions. Synthesis of codrugs typically employs reactions to form these linkers efficiently. Esterification often utilizes dicyclohexylcarbodiimide (DCC) and (DMAP) as catalysts to activate carboxylic acids for reaction with alcohols, yielding high-purity esters under mild conditions. Amidation proceeds via similar carbodiimide-mediated s between carboxylic acids and amines, frequently in one-pot sequences to minimize intermediate isolation and enhance yield. Azo linkers are synthesized through diazotization and of aromatic amines, followed by linkage to scaffolds, with optimization for to ensure balanced reduction kinetics. Cleavage mechanisms are engineered for predictability and site-selectivity. Enzymatic dominates for linkers, primarily via ubiquitous carboxylesterases that catalyze bond scission at physiological , releasing drugs with half-lives tunable from minutes to hours depending on steric hindrance. linkers undergo slower enzymatic cleavage by amidases or proteases, providing sustained release, while non-enzymatic options like pH-dependent (e.g., accelerated at acidic gastric or basic intestinal ) serve as backups. Azo linkers rely on anaerobic bacterial reduction in the gut , where azoreductases cleave the N=N bond to yield amines, with rates influenced by electron-donating substituents on the aromatic rings. These mechanisms allow for controlled release kinetics, often modeled to match the drugs' pharmacokinetic profiles. Chemical considerations emphasize dual stability: codrugs must resist degradation during manufacturing and storage (e.g., esters stable at neutral and room temperature) yet cleave rapidly to avoid accumulation. Linker avoids immunogenic fragments by selecting biocompatible motifs, such as those yielding non-toxic alcohols or carboxylic acids upon . Optimization frequently incorporates spacers, like (PEG) chains, to mitigate steric interference between moieties, enhance aqueous (e.g., increasing it by 10- to 100-fold), and fine-tune release rates without altering the core linker chemistry.

Therapeutic Advantages

Pharmacokinetic Improvements

Codrugs enhance by chemically linking drugs to mask polar functional groups, thereby increasing and improving gastrointestinal absorption or across biological barriers. For instance, the liposome-encapsulated codrug of lamivudine and (LMX) demonstrated a relative oral of 1074.8% compared to a lamivudine suspension, attributed to improved and . Similarly, in antihypertensive codrugs combining losartan or its E-3174 with inhibitors, of the active E-3174 increased from 3.5% for direct E-3174 administration to 14.6% at 10 mg/kg oral dose in rats (compared to losartan's effective delivery of the metabolite), leading to higher plasma concentrations and reduced dosing requirements. The linkage in codrugs can prolong by delaying enzymatic or chemical , extending the duration of action beyond that of individual components. A naltrexone-diclofenac codrug, delivered transdermally via microneedles, achieved sustained release over 7 days, maintaining therapeutic levels while minimizing frequent dosing. This controlled release mechanism, often mediated by stable or linkers, reduces rapid metabolism and clearance, as seen in codrugs where area under the curve (AUC) values for released actives were significantly elevated, such as 12,431 h·ng/mL for E-3174 from an antihypertensive codrug compared to lower levels from monotherapy. Targeted delivery is facilitated by designing codrugs for site-specific cleavage, leveraging enzyme gradients to concentrate active drugs in desired tissues while limiting systemic exposure. The classic example is , a codrug of and 5-aminosalicylic acid linked by an azo bond, which is cleaved by colonic azoreductase bacteria to release the component locally, enhancing tissue penetration in the gut with minimal absorption of the intact form. In skin-targeted applications, hydroquinone-tranexamic acid codrugs showed 7.2-fold higher deposition in the and compared to hydroquinone alone, due to affinity for viable layers. Codrugs can mitigate the first-pass effect, particularly through non-oral routes, by initially bypassing hepatic metabolism and allowing gradual release into systemic circulation for higher plasma levels of actives. codrugs, such as those employing phenol linkages, avoid presystemic liver extraction entirely, resulting in improved overall and reduced clearance rates. For example, in delivery systems, this approach has led to enhanced flux and sustained without the losses typical of . The role of linkers in conferring metabolic stability briefly underscores these gains, as they control the timing and site of drug liberation.

Reduction of Side Effects

One key mechanism by which codrugs reduce side effects is the inactivation of toxic functional groups until they reach the target site, thereby preventing off-target effects such as gastrointestinal irritation from nonsteroidal anti-inflammatory drugs (NSAIDs). In these codrugs, the group of the NSAID, which contributes to gastric mucosal damage, is masked through esterification with a promoiety, rendering the compound stable in the acidic gastric environment (pH 1.2) and cleavable only in neutral plasma (pH 7.4) to release the active drug. Codrugs also employ synergistic balancing by chemically linking a primary therapeutic agent with a protective moiety, such as an , to counteract inherent toxicities. For example, flurbiprofen- mutual prodrugs pair the anti-inflammatory NSAID with moieties like or , enhancing overall tolerability by mitigating while preserving efficacy. The enhanced pharmacokinetic properties of codrugs enable decreased dosing frequency, leading to lower cumulative drug exposure and diminished risks like associated with repeated administration. These strategies yield specific benefits, including a markedly lower incidence of ation; preclinical models demonstrate ulcer index reductions of approximately 50-80% compared to unmodified NSAIDs, as seen in studies with prodrugs ( index 0.56-1.34 versus 3.07 for the parent drug) and NSAID conjugates (0.306-0.376 versus 0.882).

Notable Examples

Gastrointestinal Codrugs

Gastrointestinal codrugs represent a class of prodrugs engineered to target the colon through enzymatic cleavage by gut microbiota, enabling localized delivery of anti-inflammatory agents for disorders such as ulcerative colitis (UC) and inflammatory bowel disease (IBD). One of the earliest and most prominent examples is sulfasalazine, an azo-linked conjugate of 5-aminosalicylic acid (5-ASA) and sulfapyridine, designed to address the poor absorption of 5-ASA from the upper gastrointestinal tract. Upon oral administration, approximately 70-90% of intact sulfasalazine reaches the colon, where azoreductase enzymes produced by colonic bacteria cleave the azo bond, releasing 5-ASA for local anti-inflammatory action via inhibition of nuclear factor kappa B (NF-κB) and tumor necrosis factor-alpha (TNF-α). This targeted release ensures about 30% of the administered dose is delivered as 5-ASA to the colonic mucosa, minimizing systemic exposure. Sulfasalazine was first approved by the FDA in 1950 for the treatment of UC and remains widely prescribed, with millions of patients using it annually worldwide for induction and maintenance therapy in mild to moderate disease. Mesalazine derivatives, such as olsalazine, exemplify advancements in codrug design by eliminating the sulfapyridine carrier to reduce adverse effects. Olsalazine is a symmetric dimer of two 5-ASA molecules connected by an azo bond, which is poorly absorbed in the , allowing over 90% to reach the colon intact. There, bacterial azoreductases cleave the bond, yielding two molecules of 5-ASA for sustained local release and anti-inflammatory effects similar to those of but without sulfapyridine-related toxicities like reactions. This approach enhances tolerability while maintaining targeted delivery to the site of inflammation in UC and . Clinically, these codrugs demonstrate high efficacy in IBD management, with remission rates of 60-80% in maintenance therapy for UC, outperforming and offering advantages over monomeric 5-ASA formulations through reduced systemic exposure to carriers like . For instance, olsalazine achieves comparable relapse prevention to but with fewer dose-related side effects, supporting its use in long-term therapy. Their development was driven by the need to overcome 5-ASA's rapid absorption and metabolism, leveraging colon-specific enzymatic targeting for optimal therapeutic outcomes.

Analgesic and Anti-inflammatory Codrugs

Benorylate, an ester-linked codrug of aspirin and , undergoes to release both components, providing synergistic and effects for mild to moderate pain conditions such as . Introduced in the UK in the early 1970s, it offers improved tolerability over aspirin alone, with clinical studies demonstrating reduced ; mean fecal blood loss was 1.7 ml/day during benorylate therapy compared to 5.1 ml/day with soluble aspirin (p < 0.001). This reduction in side effects stems from the prodrug's slower release profile, minimizing direct mucosal exposure to free aspirin. NSAID-antioxidant codrugs, such as those linking to antioxidants like or via bonds, aim to mitigate and associated ulceration while preserving activity. These mutual prodrugs mask the group of the NSAID, leading to stability in gastric conditions ( 1.2) and reduced local upon oral administration. Preclinical evaluations in rat models showed ulcer indices of 0.56–1.76 for the prodrugs versus 3.07 for alone, indicating approximately 40–80% lower gastric damage, alongside comparable or superior potency in carrageenan-induced paw edema assays. The ibuprofen-amlodipine codrug targets comorbid and inflammatory , particularly in geriatric patients, by combining the NSAID's effects with the blocker's control. Synthesized via amidation, it hydrolyzes in simulated intestinal fluid ( 7.4) to release active components, demonstrating enhanced activity in carrageenan-induced and antihypertensive efficacy in fructose-induced hypertensive models, while eliminating ibuprofen's gastrointestinal adverse effects for improved cardiovascular safety. Analgesic and anti-inflammatory codrugs often exhibit enhanced potency due to synergistic release and targeted delivery. For example, certain opioid-cannabinoid codrugs have shown 1.5-fold greater analgesia in preclinical models compared to parent drugs alone. Additionally, masking reactive functional groups in codrugs can extend shelf life by preventing precipitation or degradation, as seen in polar prodrug formulations that maintain stability beyond standard expiration periods.

Challenges and Future Prospects

Limitations in Development

One major limitation in codrug development lies in the synthetic challenges associated with designing appropriate linkers that ensure balanced stability. Codrugs require linkers that remain intact during storage and systemic circulation to prevent premature release of the active components, yet must cleave efficiently at the target site; overly stable linkers hinder therapeutic release, while labile ones lead to early breakdown and reduced efficacy. This balance is particularly difficult for mutual prodrugs, where the chemical compatibility of the two parent drugs must be optimized to avoid side reactions during multi-step synthesis, often involving custom or linkages. Additionally, the high of developing and scaling these custom linkers contributes to prolonged development timelines and increased production expenses. Biological hurdles further complicate codrug efficacy due to inter-patient variability in enzyme expression and activity, which governs the activation and release of linked drugs. Enzymatic activation, often reliant on hydrolases like carboxylesterases or , can vary significantly across individuals due to genetic polymorphisms, leading to inconsistent drug release and . For orally administered codrugs, differences in gut composition exacerbate this issue, as microbial enzymes influence metabolism and can lead to variable efficacy in patients with altered . Regulatory obstacles arise because codrugs are typically classified as new chemical entities (NCEs) by the FDA, necessitating a full (NDA) process with extensive preclinical and on , , and . This classification contrasts with simpler fixed-dose combinations, which may qualify for abbreviated pathways, resulting in development timelines exceeding 10 years for codrugs compared to shorter reviews for established drug pairs. Toxicity risks pose another critical barrier, as incomplete cleavage of the linker or off-target can generate novel metabolites that accumulate and cause unforeseen adverse effects. In mutual prodrugs, the dual-drug structure increases the potential for unpredictable interactions, such as non-specific leading to systemic exposure to intermediates with heightened toxicity profiles. Economic factors limit the pursuit of codrugs, given their niche applications and high development costs relative to generic alternatives. The complex synthesis and rigorous testing required make codrugs less commercially viable for broad markets, restricting investment to specialized therapeutic areas where unmet needs justify the expense.

Emerging Applications

In , codrugs incorporating combretastatin A-4 (CA4), a vascular disrupting agent, have shown promise for enhancing tumor targeting when linked to chemotherapeutics such as . These conjugates leverage CA4's ability to collapse tumor vasculature, thereby improving the delivery and efficacy of the chemotherapeutic payload at the tumor site while minimizing systemic toxicity. Development of CA4-based codrugs has progressed since the , with preclinical studies demonstrating synergistic antitumor effects through targeted release mechanisms. In , the memantine-α-lipoic acid codrug represents an investigational approach for , combining memantine's antagonism with α-lipoic acid's properties to enhance . Preclinical evaluations indicate that this conjugate reduces oxidative damage and glutamate in neuronal models, exhibiting improved and brain penetration when formulated in solid lipid nanoparticles. Synergistic effects have been observed , with no and controlled release under simulated physiological conditions. For cancers driven by EML4-ALK fusions, such as non-small cell cancer, bivalent codrugs like ceritinib-pictilisib offer dual targeting potential through ALK and PI3K inhibition. This design uses a -sensitive linker that remains stable in the environment ( 6.4) but cleaves at physiological (7.4), enabling localized release and overcoming resistance to single-agent . Preclinical was confirmed in ALK-positive cell lines, with combination index values indicating enhanced growth inhibition at nanomolar concentrations. Emerging trends in codrug development include integration with nanoparticles for site-specific delivery, as seen in formulations loading codrugs like paclitaxel-tetrandrine for , which improve tumor accumulation and in preclinical models. Additionally, is facilitating linker optimization and personalized codrug design by predicting molecular interactions and stability, accelerating the pipeline for and applications.

References

  1. https://www.sciencedirect.com/science/article/pii/S0928098710003404
  2. https://www.tandfonline.com/doi/full/10.1080/17425247.2016.1187598
  3. https://www.ijpsonline.com/articles/mutual-prodrug-concept-fundamentals-and-applications.pdf
  4. https://www.sciencedirect.com/science/article/abs/pii/S0045206813000242
  5. https://pubmed.ncbi.nlm.nih.gov/20888411/
  6. https://pubs.rsc.org/en/content/articlehtml/2024/ra/d4ra00365a
  7. https://link.springer.com/article/10.1007/s11095-013-1147-8
  8. https://pubmed.ncbi.nlm.nih.gov/27159251/
  9. https://www.researchgate.net/publication/373171984_Nanna_Svartz_1890-1986_and_the_discovery_of_sulfasalazine
  10. https://pubmed.ncbi.nlm.nih.gov/21737530/
  11. https://pubmed.ncbi.nlm.nih.gov/5122525/
  12. https://www.researchgate.net/publication/279757622_DICLOFENAC_CODRUGS_AND_PRODRUGS-THREE_DECADES_OF_DESIGN
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC2751454/
  14. https://www.sciencedirect.com/science/article/pii/S2772417424000992
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC9290623/
  16. https://pubs.acs.org/doi/10.1021/cr200338q
  17. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290623/
  18. https://www.sciencedirect.com/science/article/abs/pii/S0223523416304767
  19. https://pubmed.ncbi.nlm.nih.gov/22085635/
  20. https://doi.org/10.1016/j.ejps.2021.105731
  21. https://pubmed.ncbi.nlm.nih.gov/23943543/
  22. https://doi.org/10.1016/j.ejps.2010.09.014
  23. https://www.researchgate.net/publication/233687014_Prodrugs_and_codrugs_as_strategies_for_improving_percutaneous_absorption
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC4968865/
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC3546748/
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC10675571/
  27. https://www.ncbi.nlm.nih.gov/books/NBK557809/
  28. https://www.mdpi.com/1422-0067/21/18/6502
  29. https://pubchem.ncbi.nlm.nih.gov/compound/5339
  30. https://www.sciencedirect.com/topics/medicine-and-dentistry/olsalazine
  31. https://pubmed.ncbi.nlm.nih.gov/1711964/
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC8189994/
  33. https://www.sciencedirect.com/science/article/abs/pii/0140673692916014
  34. https://pubmed.ncbi.nlm.nih.gov/15893274/
  35. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/benorilate
  36. https://www.bmj.com/content/3/5826/545
  37. https://rjptonline.org/AbstractView.aspx?PID=2023-16-8-71
  38. https://uknowledge.uky.edu/gradschool_diss/98/
  39. https://patents.google.com/patent/EP0986403A1/en
  40. https://sciensage.info/index.php/JASR/article/download/2430/1715
  41. https://www.mdpi.com/1999-4915/15/11/2234
  42. https://ijpsr.com/bft-article/mutual-prodrugs-a-swot-analysis/
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC3697796/
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC5718288/
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC7070911/
  46. https://www.fda.gov/drugs/development-approval-process-drugs/novel-drug-approvals-fda
  47. https://www.researchgate.net/publication/397318090_Enhancing_prodrug_development_strategies_and_challenges
  48. https://www.sciencedirect.com/science/article/abs/pii/S0223523422005621
  49. https://www.sciencedirect.com/science/article/abs/pii/S0378517315002021
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC7073869/
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC3464082/
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC7577280/
Add your contribution
Related Hubs
Contribute something
User Avatar
No comments yet.